Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Turning on tumors to study cancer progression

Nature Medicine volume 5, pages 989–990 (1999)Cite this article

Abstract

Despite the numerous oncogene signaling pathways that have been deciphered, no one is really sure whether drugs designed to target them will cause tumor regression in vivo. Several recently developed animal models of tumor induction provide insight into the prospects for oncogene-specific therapeutics.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Inducible H-RasV12G control of tumorigenesis.

References

  1. Chin, L. et al. Essential role for oncogenic ras in tumour maintenance. Nature 400, 468–472 (1999).

    Article  CAS  Google Scholar 

  2. Serrano, M. et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27–37 (1996).

    Article  CAS  Google Scholar 

  3. Gossen, M. et al. Transcriptional activation by tetracyclines in mammalian cells. Science 268, 1766–1769 (1995).

    Article  CAS  Google Scholar 

  4. Rak, J. et al. Mutant ras oncogenes upregulate VEGF/VPF expression:implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55, 4575–80 (1995).

    CAS  PubMed  Google Scholar 

  5. Pelengaris, S., Littlewood, T., Khan, M., Elia, G. & Evan, G. Reversible activation of c-Myc in skin: induction of acomplex neoplastic phenotype by a single oncogenic lesion. Mol. Cell 3, 565–577 (1999).

    Article  CAS  Google Scholar 

  6. Ewald, D. et al. Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science 273, 1384–1386 (1996).

    Article  CAS  Google Scholar 

  7. Barrington, R.E. et al. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell. Biol. 18, 85–92 (1998).

    Article  CAS  Google Scholar 

  8. Lebowitz, P.F. & Prendergast, G.C. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene 17, 1439–45 (1998).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Molecular Genetics and Centre of Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands

    Anton Berns

Authors
  1. Anton Berns
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berns, A. Turning on tumors to study cancer progression. Nat Med 5, 989–990 (1999). https://doi.org/10.1038/12421

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/12421

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing